Important new data on closely followed blood cancer treatments — including personalized CAR-T therapies from Celgene, Bluebird Bio, and Johnson & Johnson — emerged Wednesday in research abstracts released by the American Society of Hematology (ASH).
The abstracts offer preliminary looks at clinical trial data that will be presented in full at the ASH annual meeting in December. Still, even sneak peeks at new blood cancer data can sway opinions and move stock prices.
About the Author Reprints
